China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has entered into a partnership with fellow Chinese firm Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SH). The collaboration focuses on the development and manufacturing of insulin glargine, insulin aspart, and insulin lispro, with the goal of filing for approval with the US FDA. King-Friend will hold exclusive commercialization rights for these products in the US market, should they be launched. The financial details of the agreement have not been disclosed.
Joint Efforts for Global Market Expansion
Tonghua Dongbao’s human insulin is currently awaiting a regulatory decision in Europe, while insulin glargine and insulin aspart are being prepared for market filings in several developing countries. This partnership with King-Friend Biochemical is a strategic move to expand their global footprint and increase the accessibility of their insulin products.
Collaboration with Kexing Biopharm for Liraglutide Development
In a separate agreement, Tonghua Dongbao and Kexing Biopharm have agreed to develop liraglutide for 17 overseas emerging markets. This collaboration further demonstrates Tonghua Dongbao’s commitment to expanding its presence in the global pharmaceutical market and addressing the needs of patients worldwide.-Fineline Info & Tech
